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ABSTRACT
Objective We performed a review of studies of
ﬂuticasone propionate (FP)/salmeterol (SAL) (combination
inhaled corticosteroid (ICS)/long-acting β2-agonist
(LABA)) in patients with COPD, which measured baseline
(pretreatment) blood eosinophil levels, to test whether
blood eosinophil levels ≥2% were associated with a
greater reduction in exacerbation rates with ICS therapy.
Methods Three studies of ≥1-year duration met the
inclusion criteria. Moderate and severe exacerbation rates
were analysed according to baseline blood eosinophil
levels (<2% vs ≥2%). At baseline, 57–75% of patients
had ≥2% blood eosinophils. Changes in FEV1 and St
George’s Respiratory Questionnaire (SGRQ) scores were
compared by eosinophil level.
Results For patients with ≥2% eosinophils, FP/SAL
was associated with signiﬁcant reductions in
exacerbation rates versus tiotropium (INSPIRE: n=719,
rate ratio (RR)=0.75, 95% CI 0.60 to 0.92, p=0.006)
and versus placebo (TRISTAN: n=1049, RR=0.63, 95%
CI 0.50 to 0.79, p<0.001). No signiﬁcant difference was
seen in the <2% eosinophil subgroup in either study
(INSPIRE: n=550, RR=1.18, 95% CI 0.92 to 1.51,
p=0.186; TRISTAN: n=354, RR=0.99, 95% CI 0.67 to
1.47, p=0.957, respectively). In SCO30002 (n=373), no
signiﬁcant effects were observed (FP or FP/SAL vs
placebo). No relationship was observed in any study
between eosinophil subgroup and treatment effect on
FEV1 and SGRQ.
Discussion Baseline blood eosinophil levels may
represent an informative marker for exacerbation
reduction with ICS/LABA in patients with COPD and a
history of moderate/severe exacerbations.
INTRODUCTION
Inhaled corticosteroids (ICS) are an important
treatment for COPD.1 Exacerbations, deﬁned as
acute worsening of symptoms necessitating treat-
ment with antibiotics and/or systemic corticoster-
oids or hospitalisation, are a key determinant of
COPD morbidity, mortality and healthcare costs.2
Compared with placebo, ICS such as ﬂuticasone
propionate (FP) and budesonide reduce exacerba-
tions by up to 20% as monotherapy, and up to
30% in combination with a long-acting β2-agonist
(LABA).3–5 National and international guidelines
on the management of COPD1 6 recommend that
patients with COPD at risk of exacerbations receive
ICS/LABA maintenance therapy.
The TOwards a Revolution in COPD Health
(TORCH) study showed that ICS treatment was
associated with an increased risk of non-fatal pneu-
monia in patients with FP-treated COPD,7 now
recognised as an ICS class effect.8 The reconsider-
ation of potential risks associated with ICS treat-
ment, weighed against its known beneﬁts, has
motivated the search for biomarkers to inform
COPD treatment decisions.9
A predictive marker for ICS (or ICS/LABA)
effectiveness in preventing COPD exacerbations
could aid clinical decision-making by identifying
patients likely to gain the most beneﬁt from
ICS-based treatment. Blood eosinophil count may
provide such a marker. Studies have demonstrated
associations between airway eosinophilia and
exacerbations of chronic bronchitis10 and COPD.11
Exacerbations are heterogeneous, presenting as one
of four distinct phenotypes, and airway eosino-
philia in the stable state was found to be predictive
of subsequent exacerbation phenotype.12
Relationships between sputum eosinophilia and
steroid responsiveness in COPD have also been
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Key messages
What is the key question?
▸ Is a pretreatment blood eosinophil level of
≥2% (vs <2%) associated with a greater
reduction in COPD exacerbation rate with
inhaled corticosteroids/long-acting β2-agonist
combination?
What is the bottom line?
▸ A retrospective analysis of data from three
randomised, controlled trials of at least 1-year
duration supported the hypothesis that there is
greater response to ﬂuticasone propionate/
salmeterol, compared with placebo or
long-acting anti-muscarinic agents, in
individuals with a pretreatment blood
eosinophil level of ≥2% compared with those
with a pretreatment blood eosinophil level of
<2%.
Why read on?
▸ A blood test for eosinophil levels could be
employed as a simple biomarker for clinical
decision-making in patients with
moderate-to-severe COPD and a history of
exacerbations.
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reported.13 14 The use of systemic corticosteroids in patients
experiencing acute exacerbations of COPD has shown greater
beneﬁt in patients with a blood eosinophil level of ≥2% versus
those with <2%.15 16 There is also evidence for an association
between airway eosinophilia with response to systemic corticos-
teroids for FEV1
14 17 and quality of life.13 A recent retrospective
analysis of data from two parallel 1-year studies of once-daily
ICS/LABA, ﬂuticasone furoate (FF)/vilanterol (VI) in patients
with moderate-to-very severe COPD showed a greater reduction
of moderate and severe exacerbations in patients with a blood
eosinophil level ≥2% vs <2% when treated with FF/VI com-
pared with VI alone.18 19
To investigate the potential of blood eosinophil level as a
marker for the preventive efﬁcacy of ICS or ICS/LABA on
exacerbations, we reanalysed data from studies comparing ICS
or ICS/LABA combination therapy (FP/salmeterol (SAL)) with a
long-acting antimuscarinic (LAMA), LABA or placebo according
to baseline eosinophil categories.
METHODS
Study selection
Parallel-group, double-blind, randomised clinical trials of FP or
FP/SAL that included at least one non-ICS comparator and were
at least 24 weeks in duration were identiﬁed in the GSK Clinical
Study Register and reviewed for inclusion in this retrospective
analysis. Studies in which blood eosinophil levels were not
recorded at baseline or screening (ie, before randomisation)
were excluded. In total, six studies met the criteria, three of
which were ≥1 year in duration: INSPIRE (SCO40036;
NCT00361959),20 TRISTAN (SFCB3024)3 and SCO30002.21
One additional study was identiﬁed,22 but was excluded, as
eosinophil data were only available in a subset of subjects.
Analysis population
The primary analysis population of each study was used as the
analysis population for this retrospective analysis.
The 2-year INSPIRE (SCO40036) trial was designed to study
exacerbations and compared twice-daily FP/SAL 500/50 μg with
once-daily tiotropium 18 μg in 1323 patients with severe or
very severe COPD (post-bronchodilator FEV1 <50% pre-
dicted).20 Patients had a history of COPD exacerbations in the
year prior to randomisation. The primary outcome variable was
the rate of exacerbations requiring treatment with systemic cor-
ticosteroids or antibiotics, or necessitating hospitalisation.
TRISTAN (SFCB3024) was a 1-year study comparing twice-
daily FP/SAL 500/50 μg with its monocomponents and placebo
in 1465 patients with moderate-to-severe COPD (pre-
bronchodilator FEV1 25–70% predicted).
3 Patients had a
history of ≥1 treated exacerbation/year in the 3 years prior to
trial entry. The primary outcome variable was change from base-
line in pretreatment FEV1 (after patients had abstained from
bronchodilators for ≥6 h and from study medication for ≥12 h)
at study end. Number of moderate and severe exacerbations was
a secondary endpoint.
SCO30002, another 1-year study, compared twice-daily FP/
SAL 500/50 μg with FP 500 μg and placebo in 387 patients with
moderate-to-severe COPD (FEV1 ≤70% predicted) with and
without a history of exacerbation. The primary endpoint was
time to ﬁrst moderate/severe exacerbation. Number of moderate
and severe exacerbations was a secondary endpoint.
Three additional studies met the selection criteria, and were
each 24 weeks in duration. SFCA3006 compared the same daily
FP/SAL dose as the longer-duration studies (FP/SAL 500/50 μg)
with its monocomponents and placebo.23 SFCA3007 and
SCO100470 compared FP/SAL 250/50 μg with its monocompo-
nents and placebo, and with SAL alone, respectively.24 25 These
studies included the following numbers of patients with eosino-
phil count data: 670 (SFCA3006), 716 (SFCA3007) and 1020
(SCO100470). In SFCA3006 and SFCA3007, subjects were
withdrawn after an exacerbation necessitating hospitalisation,
oral corticosteroid treatment, or having >3 antibiotic-treated
exacerbations; in SCO100470 patients were withdrawn if they
had >1 moderate, or ≥1 severe, exacerbations. Since moderate
and severe exacerbation rates, our primary parameter of interest,
could not be calculated from these 24-week studies, the avail-
able data from these studies are presented in online supplemen-
tary material.
With the exception of SCO30002, blood eosinophil levels
were measured by a central laboratory using standard cell count-
ing procedures. SCO30002 used local laboratories.
Statistical analysis
The retrospective analysis was conducted in accordance with a
predeﬁned analysis plan (see online supplementary material).
The comparators were such that pooling of the data was not
considered appropriate. The last pre-randomisation drug blood
eosinophil level was used to dichotomise study participants
according to blood eosinophil level of <2% vs ≥2%. In an add-
itional preplanned analysis, an absolute eosinophil count of
200/mm3 was used to dichotomise the data. A post hoc analysis
of a 3% cut-off level was also carried out. The main outcome of
interest was moderate/severe exacerbation rate (≥1-year studies
only). Time to ﬁrst moderate/severe exacerbation, change from
baseline in FEV1, rate of decline in FEV1 (TRISTAN and
INSPIRE only), and St George’s Respiratory Questionnaire
(SGRQ) score were analysed, data permitting. Weighted mean
FEV1 over the study period was analysed to provide a single
on-treatment assessment (post hoc to the analysis plan). The
primary treatment comparisons of interest were FP/SAL versus
non-ICS comparators (SAL, tiotropium or placebo) and FP
versus placebo. SAL versus placebo and FP/SAL versus FP were
examined, but were not predeﬁned comparisons of interest.
Moderate/severe exacerbation rates were analysed, for studies
of ≥1 year in duration, using a negative binomial model, with
number of recorded on-treatment moderate/severe exacerbations
per patient as the response variable. Explanatory variables were
treatment group, sex, % predicted FEV1 at baseline, frequency
of prior exacerbations (0 (SCO30002 only), 1, ≥2) within the
past year (data not available for TRISTAN), eosinophil sub-
group, and eosinophil subgroup by treatment interaction. Log
treatment exposure per patient was included as an offset vari-
able. Point estimates and 95% CI for treatment differences were
obtained for treatment comparisons of interest. A post hoc ana-
lysis of rate of exacerbations requiring oral corticosteroids or
antibiotics by eosinophil level was carried out.
Analysis of time to ﬁrst moderate/severe exacerbation was per-
formed using a Cox’s proportional hazards model including
covariates for treatment group, sex, % predicted FEV1 at base-
line, frequency of prior exacerbations (INSPIRE, SCO30002,
SCO100470), eosinophil subgroup, and eosinophil subgroup by
treatment interaction. HRs for treatment comparisons of interest
were calculated together with associated 95% CI and p values.
Kaplan–Meier survival probability estimates were calculated for
each treatment and eosinophil subgroup.
FEV1 was analysed using data as collected in each study:
trough (INSPIRE, SCO100470), pre-bronchodilator
(SFCB3024; SCO30002), post-bronchodilator (TRISTAN) and
pre-dose (SFCA3006, SFCA3007). Weighted mean FEV1 over
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the duration of the study was derived from available data by cal-
culating the area under the curve using the trapezoidal rule.
Treatment differences in weighted mean FEV1 were analysed
using an analysis of covariance with covariates of age, sex, base-
line FEV1, treatment group, eosinophil subgroup, and treatment
group by eosinophil subgroup interaction. Point estimates and
95% CIs of difference in FEV1 were obtained for treatment
comparisons of interest.
SGRQ data were analysed using mixed model repeated mea-
sures including covariates of age, sex, baseline SGRQ, treatment
group, eosinophil group, nominal day, and pairwise interactions
of day by baseline, eosinophil group and treatment group, and
the three-way interaction of day by treatment by eosinophil.
Point estimates and 95% CIs were calculated for treatment com-
parisons of interest at each nominal day.
Statistical analyses were performed using the Harmonisation
of Analysis & Reporting Program (HARP) system (GSK,
Harlow, UK) using SAS V.9.1.3 or later.
RESULTS
Patient demographics and baseline characteristics
COPD patient demographics were generally similar across the
three ≥1-year studies (tables 1–3), although patients in INSPIRE
had a lower post-bronchodilator % predicted FEV1. A total of
1269 (INSPIRE), 1403 (TRISTAN) and 373 (SCO30002)
patients had eosinophil data available. Most participants were
male, aged ≥60 years, and with a smoking history averaging ≥
approximately 40 pack-years. Approximately half of patients
were current smokers. In all three studies, a greater proportion
of patients with eosinophils <2% vs ≥2% were current smokers
(tables 1–3). No other consistent trends between eosinophil cat-
egories in demographic or baseline characteristics were
observed, including previous exacerbation history.
The proportions of patients categorised into each eosinophil
subgroup were consistent across the treatment arms in all three
studies (tables 1–3). A larger overall proportion of patients had
eosinophil levels ≥2% in the TRISTAN study than in INSPIRE
or SCO30002 (ﬁgure 1). Additional demographic and baseline
data, for the ≥1-year and 24-week studies, are provided in
online supplementary tables S1 and S2 and ﬁgure S1. For
TRISTAN, where eosinophil measurements were available at
multiple time points throughout the study, most patients were
categorised in the same category (<2% vs ≥2%) at baseline and
at week 24 or 52 (see online supplementary ﬁgure S2).
Moderate/severe exacerbation rate
Across all three ≥1-year studies, numerically greater percentage
reductions in moderate/severe exacerbation rates in patients
receiving FP/SAL versus placebo and LAMA were observed in
those with baseline eosinophil levels ≥2% vs <2% (ﬁgure 2).
This was also seen for FP and SAL versus placebo in those
studies having these arms. The adjusted mean exacerbation
rates by treatment according to baseline eosinophil subgroup
(<2%, ≥2%) are reported in online supplementary table S3.
An analysis of INSPIRE and TRISTAN according to a 3%
blood eosinophil level cut-off is reported in online supplemen-
tary table S4. An analysis of exacerbation rate in INSPIRE,
TRISTAN and SCO30002 is reported in ﬁgure 3 (time to ﬁrst
moderate/severe exacerbation according to a 200/mm3 absolute
eosinophil count cut-off is reported in online supplementary
ﬁgure S5).
In INSPIRE (excluding a prior history of exacerbations as a
covariate), a reduction of 25% in annual moderate/severe
exacerbation rate with FP/SAL versus tiotropium was observed
in the ≥2% eosinophils subgroup (p=0.006). In the <2% eosi-
nophils subgroup, the rate of these exacerbations was 18%
higher in patients receiving FP/SAL than in those who received
tiotropium, although these treatment differences did not reach
statistical signiﬁcance (p=0.186). When prior history of exacer-
bations was included as a covariate, the overall change in exacer-
bations on treatment was less pronounced, but the trend was
similar for the ≥2% eosinophils subgroup versus the <2% base-
line eosinophils group (18% reduction vs 7% increase, respect-
ively) (ﬁgure 2). There was an imbalance in treatment arms for
history of exacerbations (in the <2% eosinophils group, 26% of
FP/SAL-treated patients had >2 exacerbations in the last
12 months, compared with 18% of tiotropium-treated patients
(table 1)).
In TRISTAN, exacerbation rates with FP/SAL were compared
with FP and SAL alone and with placebo; FP and SAL were also
compared with placebo. For all comparisons, relatively greater
reductions were observed in patients with eosinophils ≥2% vs
Table 1 Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and
treatment group: INSPIRE (SCO40036)
Characteristic
FP/SAL Tiotropium
<2% ≥2% <2% ≥2%
n 263 371 287 348
Age, mean (SD) 64.1 (8.79) 64.3 (8.06) 64.8 (8.05) 64.4 (8.46)
Male (%) 79 82 81 86
Current smokers (%) 42 35 41 36
Pack-years, median (range) 38.0 (10–140) 38.0 (–50–201)* 38.0 (4–248) 35.0 (3–151)
Post-BD FEV1% predicted, mean (SD) 38.8 (8.14) 39.3 (8.34) 39.3 (9.20) 39.5 (8.67)
FEV1% reversibility, mean (SD) 2.4 (3.14) 2.2 (4.29) 2.6 (4.34)† 2.7 (4.44)
Moderate/severe exacerbations in prior 12 months, n (%)
0 69 (26) 111 (30) 89 (31) 84 (24)
1 75 (29) 111 (30) 92 (32) 97 (28)
2 51 (19) 71 (19) 55 (19) 92 (26)
>2 68 (26) 78 (21) 51 (18) 75 (22)
*Negative value was recorded in dataset.
†n=285.
BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.
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<2% (ﬁgure 2). For the comparisons of FP/SAL, FP and SAL
versus placebo, statistically signiﬁcant reductions in the rate of
exacerbations were observed in the ≥2% eosinophils subgroup
(n=1048): FP/SAL 37% (p<0.001); FP 28% (p=0.005); SAL
30% (p=0.002). Smaller reductions versus placebo were
observed in the <2% subgroup (n=353): FP/SAL 1%; FP 18%;
SAL 14%; statistical signiﬁcance was not achieved for any treat-
ment comparison in this smaller subgroup. Comparisons of FP/
SAL versus FP or SAL did not achieve signiﬁcance in either
subgroup.
In the SCO30002 study, although the 95% CIs for all com-
parisons were wide because of the small sample size, FP/SAL
and FP were associated with a lower exacerbation rate in the
≥2% eosinophils subgroup, but the reverse was seen in patients
with eosinophil level <2%.
An analysis of the rate of exacerbations requiring antibiotics
or oral corticosteroids by a 2% eosinophil level cut-off is
reported in online supplementary tables S5 and S6.
Time to ﬁrst moderate/severe exacerbation
Time to ﬁrst moderate/severe exacerbation was analysed for all
studies (1-year studies: see online supplementary ﬁgure S3;
24-week studies: see online supplementary ﬁgure S4). In all
three ≥1-year studies, for all comparisons of FP/SAL versus
placebo, versus SAL alone, versus FP alone or versus tiotropium,
none of the treatment comparisons in the ≥2% eosinophils sub-
group were statistically signiﬁcant for time to ﬁrst moderate/
severe exacerbation. In the SCO30002 study, a statistically sig-
niﬁcantly (p=0.037) shorter time to ﬁrst exacerbation in the
FP/SAL group versus placebo was observed in the <2% group.
An analysis of time to ﬁrst moderate/severe exacerbation for
INSPIRE, TRISTAN and SCO30002 according to a 200/mm3
absolute eosinophil count cut-off is reported in online supple-
mentary ﬁgure S5.
Secondary analyses (FEV1 and SGRQ)
The magnitude of the treatment differences in FEV1, and
weighted mean FEV1 during the study, between patients with
eosinophil level <2% vs ≥2% were similar in all of the ≥1-year
studies. In TRISTAN, comparisons of FP/SAL versus FP, SAL or
placebo for weighted mean FEV1 favoured FP/SAL in both sub-
groups. Likewise, in comparisons of weighted mean FEV1 for
FP or SAL versus placebo, the active treatment was favoured in
both subgroups. There was no evidence of a treatment differ-
ence in either subgroup for INSPIRE and SCO30002 (see
online supplementary ﬁgure S6). Findings from analysis of the
Table 2 Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and
treatment group: TRISTAN (SFCB3024)
FP/SAL FP SAL Placebo
Characteristic <2% ≥2% <2% ≥2% <2% ≥2% <2% ≥2%
n 93 248 94 266 86 269 81 266
Age, mean (SD) 63.1 (8.49) 62.8 (8.80) 63.3 (8.64) 63.7 (8.57) 64.4 (8.38) 62.8 (8.47) 60.3 (8.23) 64.3 (8.50)
Male (%) 77 76 61 72 56 74 68 76
Current smokers (%) 56 50 64 49 57 50 62 44
Pack-years, median (range) 40.0 (10–124) 40.0 (10–159) 35.5 (10–105) 40.0 (10–110) 44.5 (10–140) 40.0 (10–135) 41.2 (12–131) 40.0 (10–150)
Post-BD FEV1% predicted, mean (SD) 52.4 (14.51) 51.0 (14.58) 50.5 (13.89) 51.8 (14.46) 49.1 (13.91) 50.4 (13.95) 49.1 (14.50)* 51.3 (13.98)
FEV1% reversibility, mean (SD) 3.4 (3.38) 3.9 (3.60) 2.5 (3.25) 3.9 (5.95) 3.6 (3.85) 3.3 (3.72) 3.6 (3.52)* 3.5 (4.59)
*n=80.
BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.
Table 3 Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and
treatment group: SCO30002
Characteristic
FP/SAL FP Placebo
<2% ≥2% <2% ≥2% <2% ≥2%
n 45 84 50 74 50 70
Age, mean (SD) 64.4 (9.08) 63.7 (10.50) 63.0 (9.44) 65.1 (8.13) 66.9 (9.02) 64.7 (8.62)
Male (%) 87 82 84 81 74 84
Current smokers (%) 47 40 52 39 38 34
Pack-years, median (range) 37.5 (10–90)* 35.0 (10–300) 30.5 (10–150) 38.8 (10–300) 39.0 (10–88) 30.0 (10–108)
Post-BD FEV1% predicted, mean (SD) 55.3 (11.20) 56.9 (14.07) 56.5 (11.38) 57.5 (13.46)† 55.6 (9.48) 56.2 (12.06)
FEV1% reversibility, mean (SD) 3.4 (3.06) 2.6 (4.22) 2.8 (3.49) 3.6 (3.90)† 3.5 (3.50) 3.5 (3.59)
Moderate/severe exacerbations in prior 12 months, n (%)
0 17 (38) 23 (28)‡ 19 (38) 27 (36) 18 (36) 29 (41)
1 9 (20) 22 (27)‡ 10 (20) 14 (19) 9 (18) 14 (20)
2 8 (18) 20 (24)‡ 11 (22) 16 (22) 10 (20) 17 (24)
>2 11 (24) 18 (22)‡ 10 (20) 17 (23) 13 (26) 10 (14)
*n=43.
†n=73.
‡n=83.
BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.
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24-week studies suggested similar changes in both subgroups
(see online supplementary ﬁgure S7). Similarly, for the two
≥1-year studies for which change from baseline SGRQ data
was analysed, there were no treatment differences for FP/
SAL versus any comparator in change from baseline SGRQ
score in either eosinophil subgroup (see online supplemen-
tary ﬁgure S8).
Reversibility
No relationship between bronchodilator reversibility and
eosinophil level was observed (see online supplementary ﬁgure
S9).
Safety
The incidence of pneumonia in the six studies did not appear to
have any clear relationship with eosinophil level (<2% vs ≥2%)
(see online supplementary ﬁgure S10).
DISCUSSION
We examined blood eosinophil levels as a potential biomarker
for reduction in exacerbation frequency with ICS/LABA versus
LAMA or placebo using data from six randomised, controlled
trials of FP/SAL in patients with COPD, including three that fol-
lowed patients for at least 1 year. The 2% threshold for high
versus low blood eosinophil level (at baseline) was chosen for
consistency with previous studies.15 19 The results of all studies
were consistent with the hypothesis that there is a greater reduc-
tion in exacerbation rate with ICS/LABA, compared with
placebo or LAMA, in individuals with a pretreatment blood
eosinophil level ≥2%.
The proportion of patients with a pretreatment eosinophil
level ≥2% was 50–75% across all six studies. All studies
Figure 1 Proportion of all patients with baseline blood eosinophil
level <2% and ≥2% in ≥1-year studies of ﬂuticasone propionate (FP)/
salmeterol (SAL) in patients with COPD.
Figure 2 Percentage reduction in moderate/severe exacerbation rates with ﬂuticasone propionate (FP)/salmeterol (SAL) and monocomponents for
treatment comparisons of interest in ≥1-year studies by percentage baseline blood eosinophil level in (A) INSPIRE, (B) TRISTAN and (C) SCO30002.
Analysis performed using a negative binomial regression model with covariates of either treatment, gender, history of exacerbations, baseline %
predicted FEV1, percentage eosinophil group and treatment by percentage eosinophils interaction or treatment, gender, baseline % predicted FEV1,
percentage eosinophil group and treatment by percentage eosinophils interaction. <1 favours FP or FP/SAL; >1 favours tiotropium/placebo. Note:
statistically signiﬁcant comparisons (p<0.05) shown in bold font.
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recruited patients with well-deﬁned COPD with a smoking
history averaging approximately 40 pack-years, so the inadvert-
ent inclusion of patients with asthma is unlikely to account for
any variation in baseline eosinophil levels. In TRISTAN, which
had the highest proportion of patients with elevated eosinophils,
the majority of patients (88%) were not atopic in either sub-
group. Most clinical characteristics, such as age, sex, smoking
history and baseline lung function, showed no discernible differ-
ences between those with a pretreatment eosinophil level of
<2% vs ≥2%; however, there was a slightly higher proportion
of current smokers in the <2% vs ≥2% subgroup across all six
studies.
Analysis of data from the 2-year INSPIRE study was indicative of
greater efﬁcacy with twice-daily FP/SAL 500/50 μg (vs tiotropium)
in reducing the rate of moderate/severe exacerbations in patients
with blood eosinophils ≥2% vs <2% (both with and without
including prior exacerbations as a covariate (1, ≥2)). In the 1-year
TRISTAN study, FP/SAL 500/50 μg was more effective (vs placebo)
in reducing the rate of moderate/severe exacerbations in patients
with blood eosinophils ≥2% vs <2%. In TRISTAN, FP and SAL
alone were signiﬁcantly more effective than placebo in the ≥2%
group, but not in the <2% group. Stratiﬁcation by blood eosino-
phil level ≥3% vs <3% showed similar trends for TRISTAN.
However, for INSPIRE, differences were smaller in magnitude.
This result may be due to the imbalance in exacerbation history
between the tiotropium and FP/SAL groups, which makes
interpretation difﬁcult despite correction for this in the analysis.
These ﬁndings are consistent with another recent retrospective
study in which data from two parallel randomised trials of FF/VI,
once-daily ICS/LABA, in 3177 patients with moderate-to-severe
COPD and a 1-year history of exacerbation18 were reanalysed
according to eosinophil count, using the same 2% threshold as in
the present study.19 Across all FF/VI doses, FF/VI reduced exacer-
bation rates by 29% compared with VI alone (p<0.001) in patients
with ≥2% eosinophils, and by 10% (p=0.283) in patients with
<2% eosinophils.18 The ﬁndings with ICS or ICS/LABA across our
studies appear to be consistent, the only exception being in the
TRISTAN study, in which the observation of reduced exacerbation
rates in patients with ≥2% blood eosinophils receiving SAL alone
versus placebo was unexpected. Unfortunately, there is no other
trial measuring blood eosinophils with a LABA-only group of sufﬁ-
cient size and duration to corroborate this ﬁnding.
When exacerbations requiring oral corticosteroids were con-
sidered, reductions were seen for FP/SAL versus placebo in
patients with low and high eosinophil levels, but the magnitude
of reduction was greater in the ≥2% group in TRISTAN. In
INSPIRE, reductions in exacerbations requiring oral corticoster-
oids for FP/SAL versus tiotropium were only seen in the ≥2%
group. For exacerbations requiring antibiotics in INSPIRE, tio-
tropium was favoured over FP/SAL in the <2% group (in the
≥2% group there was no evidence of a difference between
treatments).
Figure 3 Percentage reduction in moderate/severe exacerbation rates with ﬂuticasone propionate (FP)/salmeterol (SAL) and monocomponents for
treatment comparisons of interest in ≥1-year studies by absolute baseline blood eosinophil count in (A) INSPIRE, (B) TRISTAN and (C) SCO30002.
Analysis performed using a negative binomial regression model with covariates of either treatment, gender, history of exacerbations, baseline %
predicted FEV1, percentage eosinophil group and treatment by percentage eosinophils interaction or treatment, gender, baseline % predicted FEV1,
percentage eosinophil group and treatment by percentage eosinophils interaction.
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Analysis of the SCO30002 study did not show any signiﬁcant
relationship between pretreatment blood eosinophil levels and
treatment. With a sample size less than one-third that of the
other two ≥1-year studies, the study had insufﬁcient power to
show treatment differences in the eosinophil subgroups, com-
pared with the other two studies, as the wide 95% CI margins
illustrate. Furthermore, this study used local laboratories for
measuring eosinophils.
The interpretation of the time to ﬁrst moderate/severe exacer-
bation analysis was limited by lack of power resulting in wide
95% CI margins. While no treatment comparison was statistic-
ally signiﬁcant, numerical trends across all three ≥1-year studies
were consistent with the exacerbation rate analysis, and are sug-
gestive of relatively greater efﬁcacy with FP/SAL and its compo-
nents versus placebo or tiotropium in the ≥2% eosinophil
subgroup. No evidence for an effect of eosinophil levels on
response to ICS/LABA in terms of lung function or
health-related quality of life was found.
A strength of our analysis is that the studies contributing the
majority of patients (INSPIRE and TRISTAN) measured pretreat-
ment blood eosinophil levels using a central laboratory system.
Furthermore, the patients were selected in accordance with strict
inclusion criteria and had well-characterised COPD. A uniform,
consensus deﬁnition of COPD exacerbations26 was used in all
studies. Although this was a retrospective analysis, the analysis
plan was deﬁned prospectively before testing of the new hypoth-
eses. A limitation of the analysis was that in most studies there
was only a single measurement of eosinophil levels before study
treatment, and intrapatient variability of eosinophil levels in
COPD is not known. Post hoc analysis of eosinophil levels in
TRISTAN, where repeated measurements were available, showed
some variability between measurements for individual patients.
We chose to stratify our population by a blood eosinophil count
of 2%, as previous publications identiﬁed the high sensitivity of
this cut-off point for the presence of a raised sputum eosinophil
count.12 13 In addition, our previous analysis demonstrated clear
differences in the response to additional ICS using this cut-off
point.18 Post hoc analysis of this and earlier studies19 shows a
graded response to additional ICS by baseline blood eosinophil
count, whether expressed as a differential or absolute count, and
supports a cut-off point of 2%. However, we acknowledge that,
as with other biomarkers, the optimum cut-off point depends on
detailed knowledge of measurement characteristics, the question
being asked, and the likely response to that question. We also rec-
ognise that data from prospective studies are required to further
validate this cut-off point. Our ﬁndings are relevant to a popula-
tion of patients with a history of exacerbations who would be
considered for treatment with an ICS-containing regimen.
Whether the ﬁndings can be extrapolated to a wider population
with COPD and whether stratiﬁcation by blood eosinophil count
results in more effective use of ICS than other stratiﬁcation strat-
egies are important areas for further study.
In conclusion, our analysis suggests that an informative rela-
tionship exists between pretreatment blood eosinophil levels
and reduction in the frequency of COPD exacerbations with
ICS/LABA treatment. Blood eosinophil levels represent a poten-
tially important biomarker that could aid treatment decision-
making in patients with moderate-to-severe COPD. Prospective
studies are required to explore these ﬁndings further.
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